Cargando…
PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429729/ http://dx.doi.org/10.1097/01.HS9.0000975956.49127.b4 |
| _version_ | 1785090784081477632 |
|---|---|
| author | Gavrilenko, Andrey Markelov, Vladislav Volkov, Nikita Shmidt, Daniil Skiba, Yaroslav Kondakova, Elena Kirill, Lepik Fedorova, Liudmila Popova, Marina Mikhaylova, Natalya Kulagin, Alexander |
| author_facet | Gavrilenko, Andrey Markelov, Vladislav Volkov, Nikita Shmidt, Daniil Skiba, Yaroslav Kondakova, Elena Kirill, Lepik Fedorova, Liudmila Popova, Marina Mikhaylova, Natalya Kulagin, Alexander |
| author_sort | Gavrilenko, Andrey |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429729 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297292023-08-17 PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT Gavrilenko, Andrey Markelov, Vladislav Volkov, Nikita Shmidt, Daniil Skiba, Yaroslav Kondakova, Elena Kirill, Lepik Fedorova, Liudmila Popova, Marina Mikhaylova, Natalya Kulagin, Alexander Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429729/ http://dx.doi.org/10.1097/01.HS9.0000975956.49127.b4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Gavrilenko, Andrey Markelov, Vladislav Volkov, Nikita Shmidt, Daniil Skiba, Yaroslav Kondakova, Elena Kirill, Lepik Fedorova, Liudmila Popova, Marina Mikhaylova, Natalya Kulagin, Alexander PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title | PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title_full | PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title_fullStr | PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title_full_unstemmed | PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title_short | PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT |
| title_sort | pb2308: nivolumab-based therapy of relapsed or refractory primary large b-cell lymphoma of immune-privileged sites and dlbcl with secondary cns involvement |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429729/ http://dx.doi.org/10.1097/01.HS9.0000975956.49127.b4 |
| work_keys_str_mv | AT gavrilenkoandrey pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT markelovvladislav pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT volkovnikita pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT shmidtdaniil pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT skibayaroslav pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT kondakovaelena pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT kirilllepik pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT fedorovaliudmila pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT popovamarina pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT mikhaylovanatalya pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement AT kulaginalexander pb2308nivolumabbasedtherapyofrelapsedorrefractoryprimarylargebcelllymphomaofimmuneprivilegedsitesanddlbclwithsecondarycnsinvolvement |